Table 1 Baseline anthropometric and clinical *parameters.
From: Metabolomic Profile Predicts Development of Microalbuminuria in Individuals with Type 1 Diabetes
|  | Progressors (n = 102) | Non-progressors (n = 98) | p |
|---|---|---|---|
Female/male (%) | 51 | 49 | ns |
Age (years) | 34 ± 12 | 34 ± 8 | ns |
BMI (kg/m2) | 25.3 ± 3.6 | 24.9 ± 3.0 | ns |
Waist/hip ratio | 0.87 ± 0.08 | 0.86 ± 0.07 | ns |
Age of diabetes onset (years) | 15 ± 9 | 11 ± 7 | <0.004 |
Diabetes duration (years) | 19 ± 11 | 23 ± 7 | <0.0001 |
Baseline | |||
HbA1c (%) | 9.34 ± 1.65 | 8.29 ± 1.30 | <0.0001 |
HbA1c (mmol/L) | 78,6 | 68.2 | <0.0001 |
Insulin dose (IU/kg) | 0.77 [0.30] | 0.74 [0.35] | ns |
Systolic BP (mmHg) | 130 ± 15 | 129 ± 12 | ns |
Diastolic BP (mmHg) | 80 ± 10 | 77 ± 9 | <0.05 |
triacylglycerols (mmol/L) | 1.53 ± 1.17 | 1.12 ± 0.74 | <0.001 |
Total cholesterol (mmol/L) | 5.10 ± 1.03 | 4.81 ± 0.76 | ns |
HDL cholesterol (mmol/L) | 1.31 ± 0.37 | 1.24 ± 0.33 | ns |
Serum creatinine (µmol/L) | 73 ± 14 | 72 ± 12 | ns |
eGFR (mL/min/1.73 m2) | 108 ± 19 | 109 ± 13 | ns |
AER (mg/24 h) | 14 [13] | 9 [6] | <0.0001 |
ACEI/AT2RB | 12 | 4 | ns |
Statins | 10 | 6 | ns |
Follow up | |||
Follow-up time (years) | 6.8 [3.8] | 7.6 [4.1] | 0.001 |
Time to progression (years) | 3.2 [3.3] | NA | NA |
Last eGFR (mL/min/1.73 m2) | 94 ± 28 | 105 ± 12 | <0.01 |
Time to last eGFR (years) | 10.4 [7.0] | 10.6 [6.3] | ns |
Change in eGFR (mL/min/1.73 m2) | −9 [27]* | −6 [18]* | <0.0001 |
